<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075164</url>
  </required_header>
  <id_info>
    <org_study_id>Fru2.0</org_study_id>
    <nct_id>NCT02075164</nct_id>
  </id_info>
  <brief_title>Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD</brief_title>
  <official_title>Unravelling the Pathogenetic Mechanisms of Fructose in Comparison to Glucose Consumption as Multiple Hit in the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease (NAFLD) - an Exploratory Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Michael Trauner, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wiener Wissenschafts-, Forschungs- und Technologiefonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from simple fatty&#xD;
      liver over steatohepatitis (NASH) to liver cirrhosis and cancer (HCC) and is a major and&#xD;
      increasing health problem affecting nearly 40% of the general population. Moreover, NAFLD is&#xD;
      an important risk factor for progression of diabetes and atherosclerosis. However, the&#xD;
      pathomechanisms determining disease progression are poorly understood. The overall aim of&#xD;
      this project is to test the central hypothesis that excessive fructose consumption provides a&#xD;
      multiple metabolic hit in the pathogenesis and progression of NAFLD/NASH by impairment of&#xD;
      hepatic lipid homeostasis and mitochondrial function resulting in hepatic lipotoxicity with&#xD;
      inflammasome activation and disturbed interorgan cross-talk among insulin sensitive tissues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To achieve these goals we will address the following specific hypotheses that&#xD;
&#xD;
        -  Fructose-induced changes in lipid composition of hepatocellular stores determine&#xD;
           lipotoxicity which may be associated with abnormalities in mitochondrial function,&#xD;
           energy homeostasis, inflammasome activation and cellular injury in progression to NASH,&#xD;
           effects which will be compared to glucose&#xD;
&#xD;
        -  Non-invasive characterization of fructose (compared to glucose)-induced lipotoxic&#xD;
           hepatic and extrahepatic metabolic risk profiles (lipid composition and energy&#xD;
           metabolism) obtained by magnetic resonance spectroscopy (MRS) will identify patients&#xD;
           with NASH&#xD;
&#xD;
        -  Severity of fructose (compared to glucose)-induced lipotoxic lipid and adenosine&#xD;
           triphosphate (ATP) derangements (identified by MRS) critically determines the degree of&#xD;
           insulin resistance and abnormalities in hepatic glucose and lipid metabolism&#xD;
&#xD;
        -  Compensatory hyperinsulinemia, secondary to skeletal muscle insulin resistance, may be a&#xD;
           primary mechanism of hepatic lipotoxicity and progression to NASH&#xD;
&#xD;
        -  Gender differences in the hepatic and systemic metabolic response to fructose are&#xD;
           mediated by the impact of female sex hormones and their nuclear receptors on hepatic&#xD;
           lipid metabolism, mitochondrial function and inflammasome activation.&#xD;
&#xD;
        -  Age differences in the hepatic and systemic metabolic response to fructose are mediated&#xD;
           by the impact of age related alterations on hepatic lipid metabolism and mitochondrial&#xD;
           function.&#xD;
&#xD;
      These key hypotheses will be addressed by a translational research consortium including&#xD;
      hepatologists, radiologists, physicists, endocrinologists and specialist in gender medicine&#xD;
      allowing an integrated mechanistic approach to NAFLD. The strength of the current proposal&#xD;
      comes directly from bridging basic science and clinical perspectives of different disciplines&#xD;
      involved in the management of NAFLD, including cutting edge non-invasive technologies such as&#xD;
      high field MRS metabolic profiling ('virtual metabolic liver biopsy') and mechanistic in&#xD;
      vitro experiments. This project will provide novel mechanistic insights in the role of&#xD;
      fructose as emerging hepatic 'toxin' in the pathogenesis and progression of NASH, as&#xD;
      increasing health problem in Western society. Moreover, this study will clarify the impact of&#xD;
      sex and gender on fructose-induced alterations in hepatic and systemic metabolism, providing&#xD;
      a rational and scientific basis for future dietary interventions and regulatory actions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrahepatic total fat and ipid composition assessed by Magnetic resonance spectroscopy</measure>
    <time_frame>Healthy volunteers: Baseline, day 56 (8 weeks); NAFLD/NASH patients: Baseline</time_frame>
    <description>At baseline and on the last day of the study (day 56) Magnetic resonance spectroscopy will be carried out in healthy volunteers. (Prior and after double-blinded fructose versus glucose consumption for 8 weeks in each healthy volunteer).&#xD;
In NAFLD and NASH patients Magnetic resonance spectroscopy will only be carried out at baseline, as this arms/groups do not undergo an oral fructose/glucose challenge.&#xD;
Baseline measures between healthy volunteers and NAFLD/NASH groups/arms will be compared to assess differences between healthy individuals and patients.&#xD;
Baseline and day 56 measures in healthy volunteers after fructose/glucose consumption will be compared to assess the influence of the dietary challenge.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will be challenged with oral 150g Fructose per day for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will be challenged with oral 167g Fructose per day for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with confirmed simple fatty liver will be compared at baseline with other arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NASH</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fructose</intervention_name>
    <description>High oral Fructose challenge (150g per day for 56 days)</description>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)</description>
    <arm_group_label>Fructose</arm_group_label>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Healthy men and women from 18 to 85, no disease history, no intake of regular&#xD;
             medication, drugs, alcohol (alcohol consumption &gt; 140 grams per week (or &gt; 30g/day)&#xD;
             45) or herbals known to affect liver physiology, male and female (1:1), BMI &lt;= 25.&#xD;
&#xD;
          2. Patients with prior confirmed (biopsy within 6 months prior to study) intrahepatic fat&#xD;
             accumulation/simple fatty liver (NAFL), HbA1c &lt; 6.5, male and female (1:1)&#xD;
&#xD;
          3. Patients with confirmed NASH (biopsy within 6 months prior to study), HbA1c &lt; 6.5,&#xD;
             male and female (1:1).&#xD;
&#xD;
          4. Signed informed consent, willing and able to perform study procedures.&#xD;
&#xD;
        General exclusion criteria (for all groups)&#xD;
&#xD;
          1. Pregnancy and lactation (blood/urine pregnancy test will be performed for female&#xD;
             volunteers at baseline and week 4)&#xD;
&#xD;
          2. Imprisoned persons&#xD;
&#xD;
          3. Declined informed consent&#xD;
&#xD;
          4. Inflammatory bowel conditions (celiac disease, Crohn's disease, ulcerative colitis)&#xD;
&#xD;
          5. Prior bariatric surgery&#xD;
&#xD;
          6. Alcoholic steatohepatitis and/or alcohol consumption &gt; 140 grams per week (or &gt;&#xD;
             30g/day) 45&#xD;
&#xD;
          7. Other liver diseases (autoimmune, genetic, cholestatic, Wilson disease,&#xD;
             Weber-Christian disease, partial lipodystrophy of the face sparing type,&#xD;
             abetalipoproteinemia, and jejunal diverticulosis with bacterial overgrowth).&#xD;
&#xD;
          8. Virus hepatitis (A, B, C)&#xD;
&#xD;
          9. Known allergic reaction to the drugs used (see material and methods)&#xD;
&#xD;
         10. Intake of drugs known to accumulate intrahepatic lipids and significantly interfere&#xD;
             with metabolism (e.g. steroids/glucocorticoids, tamoxifen, amiodarone, perhexiline&#xD;
             maleate, antiretroviral agents, tetracycline, minocycline, certain pesticides) 45&#xD;
&#xD;
         11. Inability or contraindications to perform study procedures&#xD;
&#xD;
         12. Fructose malabsorption diagnosed by two consecutive positive fructose hydrogen breath&#xD;
             test&#xD;
&#xD;
        MRI contraindications Study participants with claustrophobia Study participants carrying&#xD;
&#xD;
          -  a cardiac pacemaker&#xD;
&#xD;
          -  an insulin pump&#xD;
&#xD;
          -  operation clips&#xD;
&#xD;
          -  nerval stimulators&#xD;
&#xD;
          -  implants or prostheses (e.g. ear implants, hip prostheses, heart valve, penile&#xD;
             prosthesis)&#xD;
&#xD;
          -  metal parts or metal fragments [e.g. metallic intrauterine devices (IUDs), marrow&#xD;
             nail, metallic splinters or munition rests)&#xD;
&#xD;
          -  metallic shunts or stents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Trauner, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Trauner, Prof. MD.</last_name>
    <phone>+43140400</phone>
    <phone_ext>4741</phone_ext>
    <email>michael.trauner@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Krebs, Prof. MD.</last_name>
    <phone>+43140400</phone>
    <phone_ext>4311</phone_ext>
    <email>michael.krebs@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, General Hospital of Vienna Vienna, Vienna, Austria 1090</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Trauner, Prof. MD.</last_name>
      <phone>43140400</phone>
      <phone_ext>4741</phone_ext>
      <email>michael.trauner@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christian Kienbacher, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Traussnigg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Rechling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Michael Trauner, MD</investigator_full_name>
    <investigator_title>Professor, MD, Head and Chair of the Division of Gastroenterology and Hepatology, Department of Internal Medicine III</investigator_title>
  </responsible_party>
  <keyword>Non-alcoholic Fatty Liver Disease</keyword>
  <keyword>Non-alcoholic steatohepatitis</keyword>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

